CLINICAL TRIAL SUMMARY

MDACC Study No:RTOG0627 (clinicaltrials.gov NCT No: NCT00423735)
Title:PHASE II TRIAL OF DASATINIB IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME
Principal Investigator:Mark R. Gilbert
Treatment Agent:Dasatinib
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if dasatinib can help to
control glioblastoma multiforme that has come back after treatment with
radiation therapy and temozolomide. The safety of this drug will also be
studied.

Hide details for General InformationGeneral Information

Disease Group:Brain
Phase of Study:Phase II
Treatment Agents:Dasatinib
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:None
Supported By:NCI/CTEP
Return Visit:every 8 weeks
Home Care:Patients will take a dose of Dasatinib twice a day at home


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Mark R. Gilbert
Dept:Neuro Oncology
For Clinical Trial Enrollment:713-792-2883
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults